Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:2587:209-237.
doi: 10.1007/978-1-0716-2772-3_13.

Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy

Jessica Stoodley  1   2 , David Seoane Miraz  1   2 , Yahya Jad  1   2 , Mathieu Fischer  1   2 , Matthew J A Wood  1   2 , Miguel A Varela  3   4
Affiliations

Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy

Jessica Stoodley et al. Methods Mol Biol. 2023.

Abstract

Antisense oligonucleotides (ASOs) have shown great therapeutic potential in the treatment of many neuromuscular diseases including myotonic dystrophy 1 (DM1). However, systemically delivered ASOs display poor biodistribution and display limited penetration into skeletal muscle. The conjugation of cell-penetrating peptides (CPPs) to phosphorodiamidate morpholino oligonucleotides (PMOs), a class of ASOs with a modified backbone, can be used to enhance ASO skeletal muscle penetration. Peptide-PMOs (P-PMOs) have been shown to be highly effective in correcting the DM1 skeletal muscle phenotype in both murine and cellular models of DM1 and at a molecular and functional level. Here we describe the synthesis and conjugation of P-PMOs and methods for analyzing their biodistribution and toxicity in the HSA-LR DM1 mouse model and their efficacy both in vitro and in vivo using FISH and RT-PCR splicing analysis.

Keywords: Antisense oligonucleotides; Cell-penetrating peptide; DM1; MBNL1; Muscle; Myotonic dystrophy; PMO; Splicing.

PubMed Disclaimer

References

    1. Theadom A, Rodrigues M, Roxburgh R et al (2014) Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology 43:259–268 - DOI - PubMed
    1. Brook JD, McCurrach ME, Harley HG et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68:799–808 - DOI - PubMed
    1. Mahadevan M, Tsilfidis C, Sabourin L et al (1992) Myotonic dystrophy mutation: an unstable ctg repeat in the 3′ untranslated region of the gene. Science 255(5049):1253–1255 - DOI - PubMed
    1. Fu Y-H, Pizzuni A, Fenwick RG et al (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science (New York, N.Y.) 255(5049):1256–1258 - DOI - PubMed
    1. Taneja KL, McCurrach M, Schalling M et al (1995) Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 128:995–1002 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources